Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412336

Idiopathic Pulmonary Hemorrhage: A Multidisciplinary Approach Involving Radiology, Laboratory Medicine, and Pharmacy

Madish Sadiq Tohari [(1)] , Kholod Mohammed Ali Bakrin [(1)] , Hamoud Mohammed Hussain Juraybi [(2)] , Ibrahim Sediq Omar Tohary [(3)] , Marei Jopran Ali Al Harthi [(1)] , Hussain Ahmed Ibrahim Moashy [(4)] , Ali Mohammed Hasan Tawhari [(5)] , Majid Hamad Ali Hakamy [(6)] , Bari Ali Mogri [(4)] , Mohammad Ibrahim Alsharif [(4)]

(1) Chest Diseases Hospital, Jazan Health Cluster,Ministry of Health, Saudi Arabia,
(2) Diseases Hospital, Jazan Health Cluster,Ministry of Health, Saudi Arabia,
(3) Jazan, Ahad Al Masarihah General Hospital,Ministry of Health, Saudi Arabia,
(4) Chest Diseases Hospital, Jazan Health Cluster, Jazan,Ministry of Health, Saudi Arabia,
(5) Samtah General Hospital, Ministry of Health, Saudi Arabia,
(6) Abu Arish General Hospital, Jazan,Ministry of Health, Saudi Arabia

Abstract

Background: Idiopathic pulmonary hemorrhage (IPH) is a rare but clinically significant disorder characterized by recurrent intra-alveolar bleeding without identifiable cause. It predominantly affects children and can lead to severe respiratory compromise and chronic lung damage if not promptly recognized.

Aim: To review the clinical spectrum, diagnostic challenges, and management strategies for IPH, emphasizing a multidisciplinary approach.

Methods: A comprehensive literature-based analysis was conducted, integrating historical perspectives, pathophysiology, epidemiology, diagnostic modalities, and therapeutic interventions.

Results: IPH manifests in acute and chronic phenotypes, including diffuse alveolar hemorrhage and idiopathic pulmonary hemosiderosis. Diagnosis is primarily exclusionary, requiring elimination of vasculitic, autoimmune, infectious, and hematologic causes. Key diagnostic tools include imaging, bronchoalveolar lavage, and occasionally lung biopsy. Management relies on systemic corticosteroids as first-line therapy, with adjunctive immunosuppressants for refractory cases. Despite therapeutic advances, relapse rates remain high, and long-term complications such as pulmonary fibrosis and iron-deficiency anemia are common. Prognosis varies, with early diagnosis and treatment improving survival, while delayed recognition correlates with increased morbidity and mortality.

Conclusion: IPH demands heightened clinical suspicion, especially in pediatric patients with unexplained anemia and recurrent respiratory symptoms. Multidisciplinary collaboration and individualized immunomodulatory therapy are essential to optimize outcomes.

Keywords: Idiopathic pulmonary hemorrhage, idiopathic pulmonary hemosiderosis, diffuse alveolar hemorrhage, pediatric pulmonary disease, corticosteroids, immunosuppression.

Introduction

Idiopathic pulmonary hemorrhage is an uncommon but clinically significant disorder of the lower respiratory tract, defined by bleeding that originates within the pulmonary microcirculation and enters the distal airspaces. Although unified by the presence of intra-alveolar blood, the condition is often conceptualized along a continuum in which the tempo of disease and its underlying mechanisms shape both presentation and long-term consequences. In broad clinical terms, idiopathic pulmonary hemorrhage may be separated into acute and chronic phenotypes, a distinction that reflects whether the dominant process is an abrupt, extensive hemorrhagic event or a more indolent course characterized by recurrent episodes of bleeding and progressive iron deposition. The acute form most frequently manifests as diffuse alveolar hemorrhage (DAH), whereas chronic or insidious disease is commonly expressed as idiopathic pulmonary hemosiderosis (IPH), a syndrome that evolves after repeated occult or overt alveolar bleeding. In practice, the terminology surrounding these entities has not always been applied consistently, and the labels idiopathic pulmonary hemorrhage, idiopathic pulmonary hemosiderosis, and diffuse alveolar hemorrhage have often been used interchangeably in the literature and in clinical settings, despite the important differences in clinical trajectory and diagnostic framing that can accompany each term. The historical evolution of the

*Corresponding author e-mail: mstohari@moh.gov.sa (Madish Sadiq Tohari).
Receive Date: 11 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

concept underscores this overlap: idiopathic pulmonary hemorrhage was initially recognized in the nineteenth century when Virchow described the pathologic appearance of "brown lung induration" in 1864, an observation that presaged later understanding of iron accumulation within lung tissue. Subsequent refinements emerged through autopsy-based insights; Ceelen, in 1931, provided a more detailed characterization after postmortem examinations demonstrated substantial hemosiderin deposition in two children, thereby linking recurrent hemorrhage to iron-laden pulmonary changes. The first diagnosis made during life rather than at autopsy was later achieved by Waldenström in 1944, marking an important milestone in the clinical recognition of the disorder and laying foundations for the modern diagnostic approach.[1]

From a pathophysiological standpoint, pulmonary hemorrhage denotes the extravasation of blood into the alveolar spaces, meaning that bleeding occurs directly within the lower respiratory tract rather than being confined to proximal airways. The clinical implications of this process can be profound, because alveolar flooding with blood compromises gas exchange, promotes ventilation–perfusion mismatch, and may rapidly precipitate hypoxemic respiratory failure. In severe cases, pulmonary hemorrhage can therefore constitute a life-threatening emergency.[1] When the process is diffuse and abrupt, as in DAH, hemorrhage typically develops suddenly and involves extensive portions of the lungs rather than remaining localized to a discrete segment. This widespread distribution reflects diffuse disruption of the alveolar–capillary barrier, leading to broad intra-alveolar bleeding with clinical deterioration that may be rapid. In contrast, the chronic phenotype associated with IPH is driven by repeated episodes of alveolar hemorrhage—sometimes clinically apparent, sometimes subtle—through which breakdown products of hemoglobin progressively accumulate within the airspaces. A central feature of this chronic course is the formation and deposition of hemosiderin, an iron-containing by-product generated during hemoglobin catabolism. Over time, hemosiderin becomes a pathologic signature of recurrent bleeding: alveolar macrophages phagocytose erythrocytes and hemoglobin-derived iron complexes, converting and storing iron as hemosiderin within their cytoplasm. These "hemosiderin-laden macrophages" appear in the alveoli within a defined temporal window, typically developing within approximately 36 to 72 hours after an episode of bleeding, and they can persist within the pulmonary environment for weeks, remaining detectable for as long as eight weeks.[1] This time course has direct diagnostic relevance, as the presence of hemosiderin-laden macrophages supports prior alveolar bleeding even when active hemorrhage is no longer evident, thereby helping clinicians reconstruct the chronology of disease.



Fig. 1: Acute idiopathic pulmonary hemorrhage.

Within the broader umbrella of idiopathic pulmonary hemorrhage, a particularly rare and clinically distinctive form has been described in early life. Acute idiopathic pulmonary hemorrhage in infants (AIPHI) represents an uncommon presentation characterized by sudden pulmonary bleeding in an infant who was previously healthy, with no alternative explanation identified and without recognized co-morbidities such as prematurity that might otherwise predispose to pulmonary complications.[2] The abruptness of onset and the severity of clinical compromise frequently distinguish AIPHI from more indolent forms of hemorrhage, and the presentation may be dominated by acute respiratory distress requiring urgent evaluation and intensive supportive care.[2] While AIPHI is framed as idiopathic by definition, its separation as a clinical category emphasizes that age, baseline health status, and the absence of typical risk factors can yield a presentation that is diagnostically challenging and potentially catastrophic if not promptly recognized. The clinical spectrum of IPH itself is remarkably heterogeneous, ranging from cases that remain minimally symptomatic or even clinically silent to those that progress to fulminant respiratory failure.[3] Some individuals may experience episodic or subtle manifestations that can be overlooked, while others present with dramatic respiratory compromise that mirrors the acute DAH phenotype. This variability is not merely academic; it

directly contributes to the diagnostic complexity that surrounds idiopathic pulmonary hemorrhage. Because the condition is rare and its presentations can imitate more common pulmonary diseases, it often becomes a diagnostic pitfall for clinicians, particularly when early features are nonspecific or when bleeding is intermittent and not overt. The consequence of this diagnostic uncertainty is clinically consequential: when recognition is delayed, initiation of appropriate therapy may also be postponed, allowing ongoing hemorrhage and iron deposition to continue unchecked and increasing the likelihood of adverse outcomes. Accordingly, delayed diagnosis is repeatedly associated with delayed treatment and, ultimately, poorer prognosis.[4] In this context, heightened awareness of the disorder's diverse phenotypes—acute diffuse hemorrhage, chronic hemosiderosis, and the infantile acute presentation—serves as a critical prerequisite for timely investigation, accurate classification, and early therapeutic intervention that may alter the disease trajectory [1][2][3][4].

Etiology

Idiopathic pulmonary hemosiderosis is, by definition, a disorder in which no definitive causative factor has been established; accordingly, its etiologic basis remains uncertain, and the diagnosis is fundamentally one of exclusion. In contemporary clinical practice, IPH cannot be responsibly assigned until a comprehensive diagnostic evaluation has been undertaken to eliminate alternative and more clearly defined causes of pulmonary hemorrhage. This principle is essential because numerous systemic and pulmonary conditions may produce an indistinguishable clinical picture of intra-alveolar bleeding yet require substantially different management strategies and carry distinct prognostic implications. Therefore, the diagnostic pathway must prioritize the rigorous exclusion of immunologically mediated vasculitides and other inflammatory disorders affecting the pulmonary microvasculature, as well as inherited or acquired bleeding diatheses, including disorders of coagulation and platelet function such as von Willebrand disease.[1] Equally important, clinicians must exclude non-pulmonary sources of blood loss and systemic hemorrhagic processes that may confound the presentation or contribute to anemia and respiratory symptoms. For instance, gastrointestinal bleeding and other visceral hemorrhages can coexist with, mimic, or obscure pulmonary pathology and must be carefully ruled out through targeted history, examination, and appropriate investigations before the label of IPH is applied. Only after such differential diagnoses have been systematically considered and excluded can the term "idiopathic" be justified. Despite the absence of a confirmed cause, several potential precipitating factors have been proposed, particularly in children who may be predisposed. These putative triggers include lower respiratory tract infections, celiac disease, and hypersensitivity reactions such as cow's milk protein allergy; however, the supporting evidence remains limited and inconsistent, likely reflecting the rarity of the condition and the consequent scarcity of large, methodologically robust studies.[1][4][5] A possible association with Down's syndrome has also been reported, though the nature and strength of this relationship remain incompletely defined.[4] In contrast, earlier reports suggesting a connection with the fungus *Stachybotrys chartarum* have been subsequently challenged and are now considered refuted. Moreover, available data do not substantiate an etiologic link between IPH and tobacco smoking or other established environmental exposures.[6]



Fig. 2: Causes of pulmonary hemosiderosis.

Epidemiology

Idiopathic pulmonary hemosiderosis is an uncommon disorder with a distinctly low prevalence worldwide and a demographic profile that is strongly skewed toward the pediatric population. The condition is encountered predominantly in children, with the majority of reported cases occurring during early childhood. Epidemiologic data suggest that approximately 80% of affected individuals present before the age of 10 years, underscoring the importance of maintaining a high index of suspicion in younger patients who exhibit compatible clinical features.[1][5][7] Within this pediatric predominance, the age distribution is not uniform; rather, it demonstrates a bimodal pattern, with one peak occurring in children younger than five years of age and a second, less pronounced peak observed in those older than eleven years.[4] This bimodality suggests that distinct developmental or immunologic factors may influence disease expression at different stages of childhood and adolescence, although such mechanisms remain speculative. Although IPH is primarily regarded as a pediatric disease, cases with onset in adulthood have been well documented. Adult-onset IPH most commonly manifests before the age of 30 years, indicating that the disorder, while rare, should not be excluded solely on the basis of patient age.[1] In contrast, presentation during infancy is distinctly uncommon. While isolated cases have been described, epidemiologic evidence indicates that pulmonary hemorrhage in infants is far

more likely to have identifiable secondary causes than to represent idiopathic disease. This observation is supported by a decade-long retrospective analysis conducted in Boston, in which only four out of 154 infants evaluated for pulmonary hemorrhage met criteria for acute idiopathic pulmonary hemorrhage of infancy, highlighting the exceptional rarity of this presentation.[2] On a population level, the global incidence of IPH is estimated to range from approximately 0.24 to 1.23 cases per million individuals, reinforcing its classification as a rare disease.[4][5] With respect to sex distribution, no clear predilection has been identified among children, in whom males and females appear to be affected with similar frequency. In adults, however, a higher prevalence has been reported among men compared with women.[1][4] No consistent association with ethnicity has been demonstrated. Although familial clustering has been described in isolated reports, suggesting a potential heritable component, no definitive genetic basis has been identified to date, and the disease continues to be regarded as sporadic in most cases.[7]

Pathophysiology

The mechanistic basis of idiopathic pulmonary hemosiderosis remains incompletely elucidated, and its pathophysiology continues to be defined more by plausible models than by definitive molecular or immunologic proof. Although the initiating trigger has not been established, a subset of investigators has proposed that IPH may represent an immune-mediated disorder, potentially situated within the spectrum of autoimmune disease.[4] Support for this interpretation is limited and indirect; nevertheless, it is reinforced by the observed clinical responsiveness of many patients to immunosuppressive therapies, a therapeutic signal that is often interpreted as suggestive of immune dysregulation even when specific autoantibodies or characteristic histopathologic features are not consistently demonstrable.[8] Consequently, while an autoimmune hypothesis remains influential in clinical reasoning, it cannot yet be regarded as conclusively proven. Alternative explanatory frameworks have also been advanced to account for the heterogeneity of clinical associations described in IPH. An allergic or hypersensitivity-driven mechanism has been proposed in light of the recurrent observation of coexisting cow's milk protein allergy in some affected individuals, implying that antigen-mediated immune activation might contribute to alveolar-capillary injury in a susceptible host.[9] A genetic contribution has likewise been contemplated, prompted by occasional reports of familial clustering; however, the rarity of such clustering and the absence of an identified causative gene or reproducible inheritance pattern currently limit the strength of this argument.[9] Environmental etiologies have been considered historically as well, including earlier claims of an association with the fungus *Stachybotrys chartarum*; yet this purported link has since been refuted, diminishing the plausibility of a direct environmental fungal trigger as a unifying explanation.[9] Notwithstanding uncertainty regarding the initiating cause, the downstream biological consequences of recurrent bleeding within the alveolar compartment are better characterized. Repeated episodes of intra-alveolar hemorrhage lead to the recruitment of macrophages into the airspaces, where they phagocytose erythrocytes and process hemoglobin-derived iron, culminating in the formation and accumulation of hemosiderin within these cells. The presence of abundant hemosiderin-laden macrophages serves as both a pathologic hallmark and a functional amplifier of injury, as persistent iron deposition and ongoing macrophage activation are associated with the elaboration of pro-inflammatory cytokines. This inflammatory milieu promotes chronic alveolar-capillary interface injury and contributes to structural remodeling, including thickening of the alveolar basement membrane. Over time, these processes may progress toward interstitial fibrosis, producing a restrictive ventilatory pattern on spirometry and signaling irreversible parenchymal damage in advanced disease.[4] In the infantile presentation, by contrast, the disease process remains particularly poorly understood, with fewer data available to clarify whether the same pathways apply or whether distinct developmental vulnerabilities and triggers predominate.[2]

Histopathology

The histopathologic profile of idiopathic pulmonary hemosiderosis is characterized by a constellation of findings that reflect recurrent intra-alveolar bleeding and its sequelae, rather than a primary vasculitic injury to the pulmonary microvasculature. A defining microscopic hallmark is the prominent presence of hemosiderin-laden macrophages within the alveolar spaces, representing phagocytic clearance of erythrocytes and iron derived from hemoglobin degradation. In addition to this signature feature, tissue specimens may demonstrate fibrin deposition within the alveoli, reactive epithelial changes including type II pneumocyte hyperplasia, and variable evidence of acute inflammatory activity. Patterns consistent with organizing pneumonia may also be encountered, indicating a reparative response to repeated alveolar injury and hemorrhagic insult.[3] Collectively, these findings support a dynamic process in which hemorrhage, inflammation, and repair may coexist, with their relative prominence depending on the timing of biopsy in relation to recent bleeding episodes. A critical histologic distinction between IPH and other major etiologies of diffuse alveolar hemorrhage lies in the status of the alveolar capillary network and the presence or absence of capillaritis. In many non-idiopathic causes of DAH—particularly immune-mediated

vasculitides—capillaritis is a central feature, typified by inflammatory infiltration of the alveolar septa, injury to capillary walls, and disruption of the alveolar–capillary membrane. Such lesions imply an active microvascular inflammatory process and often correlate with systemic autoimmune disease. In contrast, IPH is notable for the absence of capillaritis, a negative finding that is diagnostically meaningful. Rather than demonstrating inflammatory destruction of septal capillaries, biopsies in IPH typically reveal thickening of the alveolar basement membrane while preserving the structural continuity of the alveolar–capillary interface. This pattern is frequently described as "bland" pulmonary hemorrhage, emphasizing that the bleeding occurs without overt vasculitic injury or necrotizing inflammation of the microcirculation.[8] The recognition of bland hemorrhage with preserved membrane integrity is therefore central to differentiating IPH from vasculitic DAH and other inflammatory capillaropathies in the appropriate clinical context. As disease duration increases and hemorrhagic episodes recur, the cumulative burden of iron deposition becomes increasingly apparent both microscopically and macroscopically. In advanced stages, the lungs may assume a distinctly brown discoloration attributable to extensive hemosiderin accumulation, mirroring the longstanding pathologic descriptions that historically drew attention to this entity.[8] This gross appearance reflects chronicity and repeated hemorrhagic events and may coexist with additional remodeling changes, reinforcing the progressive nature of untreated or refractory disease.

History and Physical

The historical and physical examination findings in idiopathic pulmonary hemorrhage are notably heterogeneous, and their expression is largely determined by whether the dominant clinical phenotype is acute or chronic. In its acute form, most commonly conceptualized within the framework of diffuse alveolar hemorrhage, the syndrome typically declares itself abruptly, with the rapid onset of severe dyspnea accompanied by hemoptysis. This presentation reflects sudden, extensive intra-alveolar bleeding with acute impairment of gas exchange, and it may progress swiftly to critical illness. When prompt recognition and urgent intervention are not achieved, acute pulmonary hemorrhage may be fatal.[1] Importantly, even among patients who initially stabilize, the subsequent trajectory can be difficult to anticipate; the course is frequently described as unpredictable, with variable recurrence and fluctuating severity over time, which complicates both early prognostication and longitudinal clinical planning.[8] In contrast, idiopathic pulmonary hemosiderosis typically evolves with a more insidious tempo, arising from recurrent episodes of diffuse alveolar hemorrhage that may be overt, intermittent, or partially occult. The cumulative consequence of repeated bleeding is reflected clinically by a spectrum of symptoms that commonly includes hemoptysis, chronic cough, exertional or progressive dyspnea, and iron deficiency anemia. Among these, anemia and dyspnea are reported most consistently and often constitute the dominant reasons for clinical evaluation.[4] While medical texts frequently cite a classical triad comprising hemoptysis, iron-deficiency anemia, and diffuse parenchymal shadowing on chest imaging, this constellation is not reliably observed in pediatric populations. In children, the triad is encountered less often than traditional descriptions suggest, thereby reducing its utility as a screening heuristic and increasing the likelihood that early disease will be overlooked when clinicians depend on this canonical pattern.[4][7] The pediatric phenotype may therefore be especially prone to under-recognition, with presentations that are fragmented across organ systems and across time.

Additional historical features may further underscore chronicity and systemic impact. Some children develop weight loss, diminished appetite, or a pattern of poor growth and failure to thrive, reflecting the metabolic burden of chronic disease, recurrent inflammatory stress, and persistent or recurrent iron loss.[1] At the severe end of the spectrum, repeated or extensive hemorrhage may culminate in hypoxemic (type 1) respiratory failure, a complication that appears particularly relevant in infants, in whom physiologic reserve is limited and deterioration can be rapid.[2][4] Notably, hemoptysis may be absent or underreported in younger children, not because hemorrhage has not occurred, but because they often swallow sputum rather than expectorate it, thereby masking a symptom that is otherwise considered a hallmark of pulmonary bleeding.[2][4] This behavioral and developmental factor introduces an important clinical pitfall: the absence of visible hemoptysis in a young child does not reliably exclude intra-alveolar hemorrhage and may paradoxically delay consideration of IPH. The infantile end of the disease spectrum introduces further diagnostic complexity. In some infants presenting with sudden-onset pulmonary hemorrhage, overt respiratory distress may not be evident, and imaging may fail to demonstrate the typical radiographic abnormalities expected with alveolar flooding. Such presentations have been described as "probable AIPHI," highlighting a clinically significant subset in which the absence of prominent respiratory signs and the lack of conspicuous chest radiology findings can obscure the diagnosis despite the occurrence of pulmonary bleeding.[6] This underscores the necessity of integrating the full clinical context—including subtle changes in color, feeding, activity, and hemodynamic status—rather than relying solely on classical respiratory complaints or radiographic confirmation [6].

A distinctive temporal pattern observed in some cases is the precedence of iron deficiency

anemia before the onset of more overt pulmonary manifestations. In these patients, anemia may be the earliest and sometimes the only prominent abnormality for an extended period, preceding respiratory symptoms by many months.[4][5] Such a presentation is clinically consequential because it may prompt extensive hematologic evaluation and empiric iron therapy without recognition of ongoing occult pulmonary blood loss. In more severe instances, anemia may become refractory to supplementation, leading to a requirement for repeated blood transfusions despite iron replacement.[4][5] This scenario should heighten clinical suspicion for persistent, unrecognized hemorrhage, particularly when anemia recurs rapidly or fails to correct as expected. The longitudinal nature of this presentation illustrates how IPH may evolve quietly, with the respiratory component emerging only after substantial cumulative disease burden has accrued. Beyond the predominant features of anemia, dyspnea, and episodic or absent hemoptysis, patients may report a range of additional symptoms that are nonspecific and variably present. These may include recurrent chest infections, intermittent fever, chest discomfort, and tachypnea, manifestations that can easily be misattributed to common pediatric respiratory illnesses or alternative chronic pulmonary conditions.[4][8] The nonspecificity of these symptoms contributes to diagnostic delay, especially when clinical encounters occur during intervals between hemorrhagic episodes, when the patient may appear relatively well and objective findings may be muted. Moreover, these symptoms may reflect not only hemorrhage itself but also secondary inflammatory responses, airway irritation, or susceptibility to infection in the setting of altered pulmonary defenses. Physical examination findings, like the history, often differ substantially depending on acuity and chronicity and may range from striking to surprisingly subtle. During an acute hemorrhagic episode, examination may reveal prominent respiratory signs such as tachypnea and increased work of breathing, but it may also be deceptively normal, particularly early in the course or in less extensive bleeding, thereby reinforcing the need for careful correlation with clinical history and ancillary testing.[1] In chronic presentations, findings may instead reflect systemic consequences of recurrent blood loss and ongoing inflammation. Pallor may be evident as a marker of anemia, and there may be signs consistent with failure to thrive or weight loss. Hepatosplenomegaly has also been described in some chronic cases, potentially reflecting systemic effects of chronic illness, extramedullary hematopoiesis, or associated conditions, though it is not universal and may be absent in many patients.[1] Importantly, the examination can remain unremarkable even in individuals with clinically significant disease, especially when bleeding is intermittent and the patient is assessed during a quiescent phase.

With progressive disease, repeated hemorrhage and persistent inflammatory remodeling may culminate in pulmonary fibrosis, and physical signs may then shift toward those associated with chronic hypoxemia and long-standing lung disease. Digital clubbing may emerge, accompanied by additional manifestations of chronic oxygen deprivation. Such findings, when present, suggest a more advanced stage and may correlate with restrictive physiology and impaired diffusion capacity, reflecting structural remodeling of the interstitium and the alveolar-capillary interface.[1] The appearance of these late signs highlights the potential for IPH to transition from episodic hemorrhagic events into a chronic fibrotic disorder with sustained functional limitation. Taken together, the history and physical examination in idiopathic pulmonary hemorrhage demand careful, developmentally informed interpretation, as the absence of classical features—particularly in children and infants—does not preclude serious disease and may, in fact, be a central reason why timely diagnosis remains challenging.[2][4][6]

Evaluation

The evaluation of idiopathic pulmonary hemosiderosis, including acute idiopathic pulmonary hemorrhage presentations, is fundamentally anchored in clinical reasoning and systematic exclusion. In acute IPH, the diagnosis is established primarily on clinical grounds once other recognized etiologies of pulmonary bleeding and alternative sources of systemic or visceral hemorrhage have been comprehensively ruled out.[2][4] This exclusionary framework is not merely procedural; it is essential because the clinical and radiologic manifestations of intra-alveolar bleeding overlap substantially with a wide range of infectious, inflammatory, cardiovascular, hematologic, and structural pulmonary disorders. Despite the importance of timely recognition, delayed diagnosis and diagnostic misattribution remain common. Reports indicate that the correct diagnosis is missed at initial presentation in approximately three-quarters of cases, with some patients experiencing prolonged diagnostic latency that can extend for several years and, in extreme circumstances, up to a decade before a definitive conclusion is reached.[7] Such delays have substantial clinical implications, as recurrent hemorrhage can perpetuate iron loss, amplify inflammatory injury, and contribute to progressive parenchymal remodeling. The principal reasons advanced for missed or delayed diagnosis include the rarity of the condition and its capacity to present in atypical or deceptively nonspecific patterns, particularly when anemia emerges in the absence of unequivocal respiratory symptoms or overt clinical signs of pulmonary bleeding.[9] In routine practice,

suspicion for IPH should be heightened in patients who demonstrate persistent, otherwise unexplained iron deficiency anemia that fails to resolve despite adequate iron supplementation, particularly when this anemia coexists with recurrent chest infections or chronic respiratory complaints and when chest radiography reveals bilateral pulmonary infiltrates.[4] Crucially, such suspicion should only crystallize after an appropriate differential diagnosis of anemia has been pursued, because nutritional deficiency, gastrointestinal blood loss, hemoglobinopathies, marrow disorders, and chronic inflammatory states may produce similar hematologic findings. The pediatric and infant populations demand even more stringent diagnostic discipline because the etiologic landscape of pulmonary hemorrhage in early life is broad and includes congenital and acquired conditions that must be explicitly excluded. In infants, for example, clinicians should actively rule out congenital heart disease, complications of prematurity, congenital and acquired pulmonary disorders, as well as congenital or acquired coagulopathies, all of which may predispose to bleeding or mimic hemorrhagic lung disease.[2] Parallel to these pulmonary-focused considerations, gastrointestinal hemorrhage must also be excluded as an alternative explanation for blood loss, particularly when anemia is prominent and hemoptysis is absent or uncertain, as gastrointestinal sources may be clinically silent or intermittently symptomatic.[6] This step is especially pertinent in young children who may swallow blood originating from the respiratory tract, thereby obscuring whether the primary bleeding site is pulmonary or gastrointestinal and increasing the risk of erroneous attribution.

Initial laboratory assessment typically provides supportive rather than diagnostic information. Routine blood tests are generally nonspecific in IPH and may demonstrate reduced hemoglobin concentration and hematocrit, reflecting ongoing or recurrent blood loss, as well as leukocytosis and an elevated erythrocyte sedimentation rate, which may signal an accompanying inflammatory response or physiologic stress.[2][8] While these findings can reinforce the plausibility of hemorrhage or inflammation, they cannot establish the diagnosis and should instead be interpreted as part of a broader evaluative synthesis. In addition, the laboratory workup must be tailored to exclude alternative causes of diffuse alveolar hemorrhage, including immune-mediated capillaritis and systemic vasculitides, although such exclusion frequently requires targeted immunologic testing and clinical correlation rather than reliance on generic indices of inflammation alone. The diagnostic challenge is heightened by the fact that anemia may precede respiratory manifestations, and inflammatory markers may fluctuate depending on the timing of testing relative to hemorrhagic episodes or concomitant infections. Imaging constitutes a central component of the evaluation, though it too must be approached with an appreciation of limited specificity. Chest radiography often provides the first objective indication of pulmonary involvement but typically reveals nonspecific patterns, including patchy, focal, or diffuse alveolar shadowing. These opacities may demonstrate characteristic distributional tendencies, such as relative apical and peripheral sparing, and air bronchograms may also be present.[8] However, these radiographic appearances overlap with pneumonia, pulmonary edema, acute respiratory distress syndromes, aspiration, and other inflammatory or hemorrhagic processes, meaning that chest x-ray rarely provides diagnostic certainty in isolation. Computed tomography of the chest, particularly high-resolution protocols, offers enhanced sensitivity and greater anatomic detail, frequently demonstrating ground-glass opacities, areas of consolidation, and interstitial patterns including reticular and micronodular opacities, sometimes accompanied by varying degrees of fibrosis.[1][3][8] These findings can be valuable for corroborating abnormalities suggested by chest radiography, clarifying the presence and distribution of alveolar filling processes, and identifying features consistent with chronicity such as fibrotic change. CT is also important for defining the extent of pulmonary involvement and for informing clinical judgments regarding disease severity, prognosis, and, in certain cases, the appropriateness and target site selection for invasive sampling.[1][3][8] Nonetheless, even high-resolution imaging cannot reliably distinguish idiopathic hemorrhage from immune-mediated or infectious causes without integration of clinical data and directed investigations.

Physiologic testing can further characterize disease impact, especially in subacute and chronic presentations. Pulmonary function tests, when feasible and when patient cooperation allows, may reveal a restrictive ventilatory defect of variable severity, consistent with reduced lung compliance and parenchymal remodeling in chronic disease.[1] Although restrictive physiology is not unique to IPH, its presence can provide objective evidence of functional impairment and may support the notion of evolving interstitial involvement, particularly in patients with recurrent hemorrhage and suspected fibrosis. Such testing can be useful longitudinally, enabling clinicians to monitor progression or response to therapy, even if it does not independently confirm etiology. Definitive diagnostic confirmation historically rests on histopathologic demonstration of characteristic findings, and lung biopsy has been regarded as the gold standard because it allows direct visualization of hemosiderin-laden macrophages and evaluation of tissue architecture.[4][5][7] However, biopsy is invasive, carries procedural risks, and may be impractical or ethically challenging in children, particularly when less invasive modalities can yield sufficiently reliable evidence for clinical decision-

making.[4][5][7] Even so, biopsy retains a selective role, especially when the differential diagnosis includes vasculitic processes that necessitate histologic confirmation or exclusion, given that management and prognosis differ substantially when capillaritis or systemic autoimmune disease is present.[9] The decision to proceed with biopsy therefore often hinges on the degree of diagnostic uncertainty, the severity and recurrence of hemorrhagic episodes, and the presence of clinical or serologic indicators suggestive of alternative pathologies.

In many settings, bronchoscopy with broncho-alveolar lavage provides a more pragmatic and diagnostically informative approach. Analysis of BAL fluid is considered a practical investigative modality and has been reported to have high sensitivity, approximately 92%, for supporting the diagnosis in appropriate clinical contexts.[7] Sequential BAL is particularly important for confirming diffuse alveolar hemorrhage: by instilling and retrieving aliquots of saline from the same bronchopulmonary segment, clinicians assess whether the red blood cell burden increases in subsequent samples, a pattern consistent with ongoing alveolar bleeding rather than procedural contamination.[7] In addition to quantifying hemorrhagic evidence, BAL fluid analysis serves a crucial exclusionary function by enabling microbiologic evaluation to rule out infectious causes that can mimic or precipitate hemorrhagic syndromes. Accordingly, the lavage specimen is typically examined for bacterial, fungal, and viral pathogens, as well as organisms associated with opportunistic infection such as Pneumocystis, and is evaluated for tuberculosis when clinically indicated.[10] This dual diagnostic and exclusionary utility makes BAL an especially valuable tool in the assessment of suspected IPH, balancing diagnostic yield against procedural invasiveness. In pediatric populations, where bronchoscopy may not always be readily available or may pose additional procedural concerns, gastric lavage fluid analysis has also been used as an alternative means of detecting hemosiderin-laden macrophages, leveraging the tendency of young children to swallow pulmonary secretions. However, this approach is limited by relatively low sensitivity, which can reduce diagnostic confidence when results are negative. Its performance can be improved through repeated sampling and testing, reflecting the episodic nature of hemorrhage and the variable presence of diagnostic cellular material in any single specimen.[4] In practice, gastric lavage findings, imaging patterns, laboratory indices, and the clinical narrative are therefore interpreted together, and the diagnosis is ultimately secured through a coherent synthesis: exclusion of alternative hemorrhagic and systemic causes, demonstration of evidence consistent with alveolar bleeding, and alignment of clinical evolution with the recognized spectrum of IPH and related idiopathic pulmonary hemorrhage presentations.[2][4]

Treatment / Management

The management of idiopathic pulmonary hemosiderosis remains challenging due to the rarity of the condition, the heterogeneity of its clinical presentation, and the absence of large-scale controlled trials to guide standardized therapy. Consequently, no universally accepted gold-standard treatment regimen has been established. Current therapeutic strategies are largely derived from case series, observational studies, and expert consensus, with the primary goals of therapy being suppression of active pulmonary hemorrhage, prevention of recurrence, mitigation of long-term lung injury, and correction of associated complications such as anemia and respiratory insufficiency. Among available interventions, systemic corticosteroids constitute the cornerstone of treatment and are most frequently employed as first-line therapy, given their anti-inflammatory and immunomodulatory properties. High-dose steroid therapy has been associated with favorable clinical responses in many patients, particularly in controlling acute symptoms and reducing the frequency and severity of hemorrhagic episodes.[4][7] Despite initial responsiveness to corticosteroids, disease recurrence remains a significant concern, and relapse rates are reported to be high, especially during dose reduction or after discontinuation. This propensity for relapse underscores the chronic and often relapsing nature of IPH and necessitates prolonged treatment courses or adjunctive immunosuppressive therapy in selected cases. A range of immunosuppressive agents, including hydroxychloroquine, azathioprine, cyclophosphamide, and 6-mercaptopurine, have been utilized either in combination with corticosteroids for severe or refractory disease or as alternative monotherapy in patients who cannot tolerate steroids or in whom corticosteroids are contraindicated.[2][4][7] These agents are generally reserved for individuals with frequent relapses, steroid dependence, or progressive disease, reflecting a strategy aimed at achieving sustained disease control while minimizing cumulative steroid-related toxicity. Therapeutic dosing strategies vary by age group and disease severity. In infants, relatively higher weight-based corticosteroid doses have been reported, with regimens of approximately 2 mg/kg/day administered over extended durations ranging from 80 to 210 days yielding encouraging outcomes in terms of symptom control and survival.[2][7] Such prolonged courses reflect both the severity of disease in this population and the need for cautious tapering to avoid precipitating relapse. In older children and adults, lower initial dosing has been suggested in some reports. For instance, a case-

based recommendation proposed initiating therapy at doses below 1 mg/kg/day, maintaining treatment until radiographic resolution of alveolar infiltrates is achieved, and subsequently implementing a gradual taper to reduce the risk of recurrence.[1] The lack of uniform dosing guidelines highlights the need for individualized treatment plans that take into account patient age, disease severity, response to therapy, and tolerance of medications.

Combination therapy has been explored as a means of improving outcomes and reducing steroid exposure. Notably, the concurrent use of azathioprine with corticosteroids has been reported in some case studies to result in superior disease control compared with corticosteroid monotherapy, potentially by enhancing immunosuppressive efficacy and facilitating steroid tapering.[1][11] However, evidence supporting combination regimens remains limited to small cohorts and anecdotal reports, and careful monitoring for adverse effects is essential, given the immunosuppressive burden associated with such therapies. In addition to corticosteroids and conventional immunosuppressants, several alternative or adjunctive treatments have been described, though their efficacy remains uncertain. These include intravenous immunoglobulin, plasmapheresis, and liposteroids, all of which have been employed in isolated cases or small series with variable success.[7] The use of these modalities is typically reserved for refractory disease or special clinical circumstances and should be considered experimental in the absence of robust supporting evidence. Dietary interventions have also been proposed in specific subgroups; notably, adherence to a gluten-free diet in patients with concomitant celiac disease and IPH has been associated with symptomatic improvement, suggesting a potential immunologic or inflammatory link in this subset of patients.[7] While this approach is not applicable universally, it underscores the importance of identifying and addressing coexisting conditions that may influence disease activity. Overall, the management of IPH requires a multidisciplinary, individualized approach that balances disease control against treatment-related morbidity. Long-term follow-up is essential to monitor for recurrence, assess pulmonary function, manage complications, and adjust therapy as needed. Given the paucity of high-quality evidence, continued reporting of clinical experience and collaborative research efforts are crucial to refining therapeutic strategies and improving outcomes for patients affected by this rare and potentially life-threatening disorder.[4][7]

Differential Diagnosis

The differential diagnosis of idiopathic pulmonary hemosiderosis is broad and must be approached systematically because IPH is, by definition, a diagnosis of exclusion and because diffuse alveolar hemorrhage has numerous etiologies with distinct management pathways and prognostic implications. A central priority is the exclusion of immune-mediated vasculitides and systemic inflammatory diseases that commonly present with pulmonary capillaritis and DAH. These include microscopic polyangiitis, pauci-immune glomerulonephritis, granulomatosis with polyangiitis (historically termed Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (historically termed Churg–Strauss syndrome), hypersensitivity vasculitis, systemic lupus erythematosus, and rheumatoid arthritis, among other connective tissue disorders.[1] Because these entities may involve multisystem disease, careful assessment for renal, cutaneous, neurologic, and musculoskeletal involvement is essential, alongside directed serologic evaluation where appropriate. Similarly, conditions characterized by immune-mediated injury to the alveolar-capillary interface, such as Goodpasture's syndrome, antiphospholipid syndrome, and lung transplant rejection, must be considered, particularly when clinical context or relevant risk factors are present.[1] Beyond vasculitic and autoimmune causes, clinicians must exclude non-inflammatory and hematologic explanations for pulmonary bleeding. Coagulopathies, including von Willebrand disease, as well as thrombocytopenia and other platelet disorders, can precipitate or exacerbate pulmonary hemorrhage and may mimic IPH when respiratory bleeding is prominent.[1] Thromboembolic disease, including pulmonary embolism with associated pulmonary infarction, can also present with hemoptysis and radiographic infiltrates, necessitating careful risk stratification and imaging when clinically suspected. Neoplastic processes, including lung cancers, may produce hemoptysis through endobronchial lesions, tumor necrosis, or vascular invasion, and therefore must be evaluated in older patients or those with concerning imaging findings.[1] Additional non-vasculitic considerations include non-traumatic lung injury, pulmonary hemangiomas, and other vascular malformations that may cause recurrent bleeding.[1] In parallel, restrictive lung disorders such as pulmonary fibrosis may enter the differential when patients present with progressive dyspnea and restrictive physiology, particularly if the history of hemorrhage is unclear or if fibrosis predominates late in the disease course.[4] Finally, given reported associations and clinical overlap, other autoimmune and inflammatory conditions such as celiac disease and cow's milk protein allergy, recurrent respiratory infections, and alternative causes of pediatric anemia should be actively considered and excluded through an appropriately comprehensive workup.[4]

Prognosis

The prognosis of idiopathic pulmonary hemosiderosis is variable and is strongly influenced by the timeliness of recognition, the rapidity with which effective therapy is initiated, and the presence of relevant co-morbidities that may amplify disease

severity or complicate management.[4][7] In general, early diagnosis and prompt commencement of therapy are associated with improved outcomes, reflecting the capacity of timely immunomodulation to suppress hemorrhagic activity, reduce cumulative lung injury, and prevent or delay progression to irreversible fibrosis.[4][11] Conversely, delayed diagnosis permits ongoing or recurrent alveolar bleeding with persistent iron deposition and chronic inflammation, thereby increasing the likelihood of restrictive lung disease, chronic respiratory insufficiency, and cardiopulmonary complications over time. Published survival estimates have historically been guarded, with an average survival reported as approximately 2.5 years in some accounts; however, outcomes are not uniformly poor, and at least one study has described substantially better longer-term survival, reporting that 86% of patients survived beyond five years.[7] Mortality rates have been cited at around 50%, illustrating the potential lethality of the disorder when disease is severe, recurrent, or inadequately controlled.[2][4][11] Notably, outcomes may differ in specific subgroups. In an infant-focused retrospective study, no mortality was recorded among the four infants diagnosed with acute idiopathic pulmonary hemorrhage of infancy, suggesting that, under certain circumstances, early recognition and supportive care may yield more favorable short-term survival in this rare presentation.[2][4][11] Age also appears to influence disease course; overall, the disorder is often described as more aggressive in children and adolescents than in adults, with a tendency toward worse outcomes in younger patients.[1] The proximate causes of death in IPH generally reflect either catastrophic acute events or progressive chronic sequelae. Fatality may occur during episodes of massive alveolar hemorrhage culminating in acute respiratory failure, particularly when bleeding is extensive and refractory.[1] Alternatively, mortality may arise from complications of chronic respiratory failure and cor pulmonale secondary to advanced pulmonary fibrosis and long-standing hypoxemia.[1] Importantly, long-term corticosteroid therapy has been associated with reductions in morbidity and mortality, likely by attenuating hemorrhagic recurrence and limiting cumulative inflammatory damage, though this benefit must be balanced against the recognized adverse effects of prolonged steroid exposure.[1]

Complications

The complication profile of idiopathic pulmonary hemosiderosis spans both acute life-threatening events and chronic organ damage that accrues through recurrent hemorrhage and prolonged inflammation. The most immediate and clinically urgent complication is hypoxic respiratory failure, which results from intra-alveolar blood compromising effective ventilation and gas exchange. In severe episodes, particularly in children with limited physiologic reserve, acute hypoxemia can progress rapidly and may be fatal without timely recognition, respiratory support, and disease-specific therapy. This acute risk underscores why suspected pulmonary hemorrhage warrants urgent evaluation, close monitoring, and a low threshold for escalation of care in high-risk presentations. Over the long term, recurrent bleeding produces sustained iron loss and is frequently complicated by iron deficiency anemia, which may be persistent, recurrent, or refractory despite supplementation. Chronic anemia contributes to fatigue, impaired growth and development in children, reduced exercise tolerance, and heightened cardiopulmonary strain. Meanwhile, repeated inflammatory injury at the alveolar-capillary interface can drive structural remodeling that culminates in pulmonary fibrosis and other restrictive lung diseases. Fibrosis, once established, may lead to chronic dyspnea, decreased diffusion capacity, reduced lung compliance, and progressive functional limitation, often accompanied by hypoxemia and, in advanced cases, secondary pulmonary hypertension with right ventricular strain. In addition to disease-intrinsic complications, treatment-related morbidity can become substantial, particularly when long-term corticosteroids and adjunctive immunosuppressive therapies are required. Prolonged steroid exposure can predispose to metabolic complications, growth suppression in pediatric patients, osteoporosis, immunosuppression with increased infection risk, hypertension, glucose intolerance, and adrenal suppression, among other effects. Immunosuppressive agents may introduce further risks, including marrow suppression, hepatotoxicity, and opportunistic infection. Therefore, comprehensive management of IPH requires not only suppression of hemorrhagic activity but also structured surveillance and mitigation of therapy-associated adverse outcomes through multidisciplinary follow-up [3][4][5][6].

Patient Education

Patient and caregiver education is a critical component of management in idiopathic pulmonary hemosiderosis because early presentation and rapid evaluation at symptom onset can materially influence clinical outcomes. Individuals and families should be counseled to seek medical attention promptly at the first appearance of concerning respiratory symptoms such as new or worsening dyspnea, cough, hemoptysis, or unexplained fatigue, as well as systemic indicators such as pallor or reduced activity that may reflect anemia or hypoxemia. This guidance is particularly important in children, in whom hemoptysis may be absent or unrecognized, and in whom subtle changes in behavior, feeding, or exercise tolerance may precede overt respiratory distress. Early hospital presentation facilitates timely assessment, exclusion of alternative causes, initiation

of supportive care, and commencement or adjustment of immunomodulatory therapy when indicated. Because IPH is idiopathic, there are no specific preventive interventions known to avert disease onset. Patients and families should be explicitly informed that the condition is not contagious, thereby alleviating concerns about transmission within households, schools, or healthcare settings. Education should also emphasize the relapsing potential of the disorder and the importance of adherence to prescribed therapy, follow-up schedules, and monitoring plans. Where long-term corticosteroids or immunosuppressants are used, counseling should include clear discussion of potential side effects, warning symptoms that warrant urgent review (such as fever or signs of infection), and the rationale for routine laboratory and clinical surveillance. In practical terms, empowering patients and caregivers with an understanding of symptom recognition, medication adherence, and risk mitigation supports earlier intervention during relapses and reduces preventable complications [9][10].

Enhancing Healthcare Team Outcomes

Optimizing outcomes in idiopathic pulmonary hemorrhage requires a coordinated interprofessional approach, reflecting both the diagnostic complexity of the condition and the breadth of organ systems and specialties implicated in its evaluation and long-term management. Although the primary pathology is pulmonary, many patients first enter the healthcare system through non-respiratory pathways, particularly primary care, with anemia as the presenting complaint. For this reason, frontline clinicians must maintain situational awareness that IPH—while rare—can underlie persistent iron-deficiency anemia that does not respond appropriately to iron supplementation. When anemia is unexplained, recurrent, or transfusion-requiring, and especially when accompanied by recurrent respiratory symptoms or bilateral infiltrates on chest imaging, early referral to pulmonology is warranted to expedite targeted investigations, including imaging refinement and evaluation for diffuse alveolar hemorrhage. Early specialist involvement can shorten diagnostic delay, which is a key determinant of morbidity and prognosis. Gastroenterology input is often essential because gastrointestinal bleeding must be excluded as an alternative source of iron loss and because swallowed pulmonary blood can obscure the true origin of hemorrhage. Rheumatology plays a pivotal role in excluding systemic autoimmune disease and vasculitides that can present with DAH, as these conditions require distinct immunosuppressive strategies and may carry additional organ-threatening complications. In patients requiring prolonged corticosteroid therapy, endocrinology involvement may become important to address steroid-related metabolic effects, growth concerns in children, adrenal suppression risk, and bone health, particularly when exposure is prolonged or cumulative doses are high. During acute decompensation—especially in hyper-acute presentations complicated by hypoxemic respiratory failure—critical care specialists are indispensable for airway management, ventilation strategies, hemodynamic support, and coordination of urgent diagnostic procedures [11]. Nursing care is central throughout the care continuum, particularly in acute stages when monitoring requirements are high and patients may require individualized support for oxygen therapy, transfusion protocols, medication administration, and family education. Respiratory therapists and physiotherapists may contribute during recovery phases and in chronic disease, especially when fibrosis develops and patients benefit from airway clearance strategies, pulmonary rehabilitation, or support in optimizing functional capacity. Because relapse and long-term treatment adverse effects are common, many patients require extended follow-up spanning years, including surveillance for recurrence, medication toxicity, growth and developmental impacts, and evolving pulmonary function impairment. Effective outcomes therefore depend heavily on sustained communication across disciplines, explicit care pathways, and timely referrals. Maintaining open channels of information exchange among the interprofessional team reduces fragmentation of care, supports rapid recognition of relapse or complications, and ultimately improves both clinical endpoints and patient experience [11].

Conclusion:

Idiopathic pulmonary hemorrhage remains a diagnostic and therapeutic challenge due to its rarity, heterogeneous presentation, and lack of definitive etiologic markers. The condition often masquerades as more common respiratory or hematologic disorders, leading to frequent delays in recognition and treatment. Such delays permit ongoing alveolar bleeding, iron deposition, and progressive inflammatory injury, ultimately predisposing patients to irreversible pulmonary fibrosis and chronic respiratory insufficiency. Early diagnosis is critical and hinges on maintaining a high index of suspicion in patients—particularly children—who present with persistent iron-deficiency anemia unresponsive to supplementation, recurrent respiratory symptoms, or bilateral infiltrates on imaging. A systematic exclusion of alternative causes, combined with evidence of alveolar hemorrhage through bronchoalveolar lavage or histopathology, forms the cornerstone of accurate diagnosis. Therapeutically, systemic corticosteroids remain the mainstay, often supplemented by immunosuppressive agents in severe or relapsing cases. Long-term follow-up is essential to monitor disease activity, manage complications, and mitigate treatment-related adverse effects. Given the absence of standardized protocols and the reliance on observational data, collaborative research and case reporting are imperative to refine management strategies. Ultimately, a

multidisciplinary approach encompassing pulmonology, rheumatology, gastroenterology, and critical care offers the best prospect for improving survival and quality of life in affected patients.

References:

1. Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. The European respiratory journal. 2004 Jul:24(1):162-70
2. Welsh SK, Casey AM, Fishman MP. Pulmonary hemorrhage in infancy: A 10-year single-center experience. Pediatric pulmonology. 2018 Nov:53(11):1559-1564. doi: 10.1002/ppul.24142.
3. Stainer A, Rice A, Devaraj A, Barnett JL, Donovan J, Kokosi M, Nicholson AG, Cairns T, Wells AU, Renzoni EA. Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. BMC pulmonary medicine. 2019 Oct 24:19(1):185. doi: 10.1186/s12890-019-0947-y.
4. Castellazzi L, Patria MF, Frati G, Esposito AA, Esposito S. Idiopathic pulmonary haemosiderosis in paediatric patients: how to make an early diagnosis. Italian journal of pediatrics. 2016 Sep 20:42(1):86. doi: 10.1186/s13052-016-0296-x.
5. Noronha N, Ramalho P, Barreira R, Roda J, Silva TR, Félix M. Severe iron-deficiency anemia as initial manifestation of pulmonary hemosiderosis in a child. Einstein (Sao Paulo, Brazil). 2018 Nov 29:16(4):eRC4505. doi: 10.31744/einstein_journal/2018RC4505.
6. Habiba A. Acute idiopathic pulmonary haemorrhage in infancy: case report and review of the literature. Journal of paediatrics and child health. 2005 Sep-Oct:41(9-10):532-3
7. Zhang Y, Luo F, Wang N, Song Y, Tao Y. Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients. The Journal of international medical research. 2019 Jan:47(1):293-302. doi: 10.1177/0300060518800652.
8. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010 May:137(5):1164-71. doi: 10.1378/chest.08-2084.
9. Taytard J, Nathan N, de Blic J, Fayon M, Epaud R, Deschildre A, Troussier F, Lubrano M, Chiron R, Reix P, Cros P, Mahloul M, Michon D, Clement A, Corvol H, French RespiRare® group. New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare(®) cohort. Orphanet journal of rare diseases. 2013 Oct 14:8():161. doi: 10.1186/1750-1172-8-161.
10. Park MS. Diffuse alveolar hemorrhage. Tuberculosis and respiratory diseases. 2013 Apr:74(4):151-62. doi: 10.4046/trd.2013.74.4.151.
11. Bakalli I, Kota L, Sala D, Celaj E, Kola E, Lluka R, Sallabanda S. Idiopathic pulmonary hemosiderosis - a diagnostic challenge. Italian journal of pediatrics. 2014 Apr 4:40():35. doi: 10.1186/1824-7288-40-35.